First National Bank of Omaha’s Jazz Pharmaceuticals JAZZ Stock Holding History

First National Bank of Omaha’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,072	Closed	-$2.62M	–	314
2025 Q1	$2.62M	Sell	21,072 -447	-2%	-$58.3K	0.18%	150
2024 Q4	$2.65M	Sell	21,519 -8,468	-28%	-$998K	0.17%	157
2024 Q3	$3.34M	Sell	29,987 -2,505	-8%	-$275K	0.21%	134
2024 Q2	$3.47M	Buy	32,492 +11,420	+54%	+$1.26M	0.23%	122
2024 Q1	$2.62M	Sell	21,072 -16,881	-44%	-$2.07M	0.18%	150
2023 Q4	$4.67M	Sell	37,953 -7,638	-17%	-$953K	0.29%	112
2023 Q3	$5.9M	Sell	45,591 -6,334	-12%	-$844K	0.38%	87
2023 Q2	$6.44M	Buy	51,925 +13,236	+34%	+$1.78M	0.37%	94
2023 Q1	$5.66M	Buy	+38,689	New	+$5.72M	0.34%	104

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

First National Bank of Omaha's JAZZ Position: Q2 2025 in Review

First National Bank of Omaha sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 21,072 shares — an estimated $2.62M sold.

First National Bank of Omaha first reported a position in JAZZ in Q1 2023 and held it in 9 quarters. The position peaked at $6.44M in Q2 2023. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

First National Bank of Omaha reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
First National Bank of Omaha sold 21,072 Jazz Pharmaceuticals shares in Q2 2025, an estimated $2.62M.
First National Bank of Omaha first reported a position in Jazz Pharmaceuticals in Q1 2023 and held it in 9 quarters.
First National Bank of Omaha's Jazz Pharmaceuticals position peaked at $6.44M in Q2 2023.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on First National Bank of Omaha's 13F filing for Q2 2025, filed 10 Feb 2026.